Pyrrolotriazine inhibitors of kinases
US6982265B1 · kind B1 · utility
64Cited by
6References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 18, 2000 |
| Grant date | Jan 3, 2006 |
| Priority date | — |
| Expiry date | May 18, 2020 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D487/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof.The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2, FGFR-1, PDGFR, HER-1, HER-2, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.